Navigation Links
2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning

San Diego, CA (PRWEB) May 24, 2013

Resource4thePeople is informing consumers today of the latest update involving allegations that the use of the popular antibiotics Zithromax and Zmax SR (azithromycin) can allegedly cause potentially fatal irregular heart rhythms.

The Canadian Broadcasting Company reported on May 17, 2013* that Health Canada has joined the U.S. Food and Drug Administration in warning that Zithromax can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm.

The medications are most frequently used for bronchitis, pneumonia, chest infections, urinary tract and other common infections.

The CBC said that the advisory from Health Canada says a "small absolute increase in the risk of cardiovascular deaths was observed in patients taking azithromycin as compared to those who took no antibiotics and those who took amoxicillin in a recent study."

Resource4thePeople also is announcing it will continue to provide consumers access to a national network of attorneys offering free legal consultations to patients who suffered alleged serious heart problems as a result of their use of Zithromax.

“The recent health warning issued in Canada that follows concerns issued by the FDA about Zithromax and the allegations of serious side effects has increased the number of recent inquiries about legal rights,” said Resource4thePeople. “Therefore, we will continue to provide consumers with consultations informing them about their legal options to seek compensation for alleged side effects from the use of these medications.”

The increase in consumer inquiries stems from concerns about side effects from the antibiotics issued May 17, 2012 by the Food and Drug Administration** and a respected medical journal*** about whether patients who use the medications are at higher risk of suffering cardiac problems, said Resource4thePeople.

“We have now added additional resources to investigate claims of health problems caused by the use of the antibiotics sold as Zithromax, the Z-Pak and azithromycin,” said Resource4thePeople.

“We will be able to provide the legal options that may be available for consumers to seek compensation for such expenses as medical costs, pain and suffering, loss of wages and other expenses that may have been incurred.”

Resource4thePeople said a large number of the legal inquiries focused on the issuance by the FDA of a Safety Information Report** “on risk of cardiovascular death” in connection with the use of Zithromax.

In that report, FDA officials said that they have been made aware of a study*** published in the New England Journal of Medicine in which medical researchers found a higher percentage of cardiovascular deaths among patients treated with azithromycin (Zithromax) than with other antibiotics or no drugs.

The FDA announced that it is reviewing the findings of this study and said it will inform health care professionals and consumers about the results of this review after its completion.

The FDA also passed on this information about the review and updated warnings on the medication’s labels about health risks:

“Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP.

“The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low.

“The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.”

The FDA also recommended that patients who are taking azithromycin should not stop taking their medicine without talking to their health care professional and that physicians “should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering macrolides.”

“In its Safety Information Report the FDA also encouraged patients and health care professionals to report adverse events or side effects caused by the use of these medications to the agency,” said Resource4thePeople.

“While the FDA is fulfilling its role of monitoring the safety of drugs such as Zithromax we are responding to reports from patients who are seeking information about what their legal rights may be and we are committed to providing that information on a case-by-case basis.”

The New England Journal of Medicine study*** included research compiled from information accumulated from about 350,000 patients who were treated with azithromycin over a 15-year period and concluded that these patients were one and a half times more likely to suffer cardiovascular sudden death than patients treated with other antibiotics.

Antibiotics are among the most prescribed medications and azithromycin is most commonly chosen by doctors to treat a variety of bacterial infections.

One of the factors that made Zithromax so popular was the fact that it could be taken as a five-day treatment while most other antibiotics are prescribed to be taken over a 10-day treatment plan.

“The fact that there were so many individuals included in this massive research study reported in the New England Journal of Medicine study and that the FDA is now reviewing this material has increased concerns by many consumers who are telling us that they were treated with this medication,” said Resource4thePeople.


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
3. Wright & Schulte File Skechers Lawsuit on Behalf of Ohio Woman Who Fell, Suffered Broken Wrist Allegedly Due to Use of Skechers Shape-Ups
4. Wright & Schulte LLC Files Transvaginal Mesh Lawsuit on Behalf of Woman Allegedly Injured by Align Urethral Support System
5. Warning Claim on Alleged Defective Wright Hip Implant Lawsuit Dismissed: AttorneyOne Informs
6. Wright & Schulte LLC Files Transvaginal Mesh Lawsuit on Behalf of Ohio Woman Allegedly Injured by American Medical Systems’ SPARC Sling System
7. Skechers Lawsuit Filed by Wright & Schulte, Utah Plaintiff Allegedly Suffered Serious Ankle Injuries Due to Shape-Ups Defective Design
8. Skechers Lawsuit on Behalf an Ohio Woman Who Sustained Serious Ankle Injury Allegedly Due to Shape-Ups' Defective Design Filed by Wright & Schulte LLC
9. Skechers Foot Fracture Lawsuit Filed on Behalf of Nevada Woman Who Suffered a Fracture Allegedly Due to Skechers Shape-Ups Toning Shoes, Reports Wright & Schulte LLC
10. Skechers Injury Lawsuit Filed on Behalf of an Alabama Man Who Suffered Severe Leg Fracture Allegedly Due to Skechers Shape-Ups Toning Shoes, by Wright & Schulte LLC
11. Law Firm Warns Patients Who Have Received Alleged Defective Smith & Nephew Hip and Knee Replacement Systems
Post Your Comments:
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... ... ... is the first health care provider in the region to offer the vBloc® Therapy ... vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients over ... to 45 kg, or a BMI of at least 35 to 39.9 kg with a ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... oncology and hematology continuing medical education (CME), today announced that the first annual ... Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers are ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... there are professionals who believe that with innovative technologies and under the right ... patient to get the benefit of a dual-approach to his or her therapeutic ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015  Athletic apparel company Tommie Copper ... pay $1.35 million to settle Federal Trade Commission ... compression clothing would relieve severe and chronic pain ... Tommie Copper,s proposed settlement ... its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
Breaking Medicine Technology: